Astellas Pharma Inc. (ALPMF) News Nov 7, 2014, 12:00

New Post Public Reply Private Reply Replies (0) Message Board

Nov 15, 2014 at 12:31 PM

Astellas Pharma Inc. (ALPMF) News Nov 7, 2014, 12:00 a.m.
MarketWatch News on ALPMF
Japan stocks drop, as China shares extend gains 2:30 a.m. April 6, 2012 - V. Phani Kumar
Japan shares edge lower as yen strengthens 7:36 p.m. Oct. 25, 2010 - Myra P. Saefong
Japan shares range-bound in early trade, pre-data 7:38 p.m. June 27, 2010 - Myra P. Saefong
Japanese shares end the morning session higher 10:04 p.m. June 23, 2010 - Myra P. Saefong
Japan shares fall; pharmaceuticals among decliners 7:36 p.m. May 16, 2010 - Myra P. Saefong
Japan shares climb as chip maker shares advance 7:35 p.m. May 12, 2010 - Myra P. Saefong
Japan budget highlights fiscal quandary 12:01 a.m. March 3, 2010 - Lisa Twaronite
Japanese drug makers put up a fight 10:29 p.m. March 2, 2010 - Myra P. Saefong
Japan shares near flat as drug makers weaken 7:35 p.m. March 2, 2010 - Myra P. Saefong
Japan shares up; chip makers gain amid Nasdaq rise 7:28 p.m. March 1, 2010 - Myra P. Saefong
Updates, advisories and surprises 7:31 p.m. Aug. 3, 2009 - MarketWatch
Astellas Pharma profit, sales slip on stronger yen 1:38 a.m. Aug. 3, 2009 - Lisa Twaronite
Astellas Pharma April-June net profit 44.0 bln yen 1:17 a.m. Aug. 3, 2009 - Lisa Twaronite
FDA panel urges clearance for Cardiome-Astellas heart drug 3:55 a.m. Dec. 12, 2007 - Robert Daniel
Stocks in focus for Thursday 6:00 p.m. May 30, 2007 - MarketWatch
Theravance: EMEA validates telavancin application 4:01 p.m. May 30, 2007 - Gabriel Madway
Stocks in focus for Tuesday 6:08 p.m. May 14, 2007 - MarketWatch
CV Therapeutics submits regadenoson application to FDA 3:38 p.m. May 14, 2007 - Gabriel Madway
Stocks in focus for Wednesday 7:41 p.m. Feb. 20, 2007 - MarketWatch
Theravance: FDA accepts NDA for telavancin 5:56 p.m. Feb. 20, 2007 - Gabriel Madway
Loading more headlines...
Advertisement
Other News on ALPMF
FibroGen on deck for IPO 1:46 p.m. Nov. 10, 2014 - Seeking Alpha
10-Q: MEDIVATION, INC. 4:54 p.m. Nov. 6, 2014 - Edgar Online - (EDG = 10Q, 10K)
Astellas antifungal tagged an Orphan Drug 12:44 p.m. Nov. 3, 2014 - Seeking Alpha
Astellas Pharma's (ALPMF) CEO Yoshihiko Hatanaka on Q2 2014 Results - Earnings Call Transcript 1:33 p.m. Oct. 31, 2014 - Seeking Alpha
CHMP supports Xtandi label expansion 9:14 a.m. Oct. 24, 2014 - Seeking Alpha
10-Q: MEDIVATION, INC. 3:34 p.m. Aug. 7, 2014 - Edgar Online - (EDG = 10Q, 10K)
Astellas Pharma's (ALPMF) Q2 2014 Results - Earnings Call Transcript 12:07 p.m. Aug. 1, 2014 - Seeking Alpha
Medivation, Astellas look to widen use of Xtandi cancer drug 8:12 a.m. March 18, 2014 - Seeking Alpha
Aveo, Astellas ending Tivozanib deal, colon-cancer work halted 7:29 a.m. Feb. 14, 2014 - Seeking Alpha
Ram Selvaraju: A Pair Of Companies Ride The Sea Change In Cancer Therapeutics 2:22 p.m. Feb. 7, 2014 - Seeking Alpha
Aveo ends trial of cancer drug due to low enrollment 7:46 a.m. Jan. 30, 2014 - Seeking Alpha
Seattle Genetics Will Exceed And Immunogen Will Meet Market Expectations 11:09 a.m. Jan. 25, 2014 - Seeking Alpha
Aveo says lead drug unlikely to succeed in colon cancer study, -15% 11:06 a.m. Dec. 13, 2013 - Seeking Alpha
10-Q: MEDIVATION, INC. 4:33 p.m. Nov. 12, 2013 - Edgar Online - (EDG = 10Q, 10K)
The New Doctor in the House: Consolidation 5:01 a.m. Feb. 3, 2011 - SmartMoney
Astellas's Strong Treatment For OSI 3:49 p.m. March 1, 2010 - The Wall Street Journal Interactive Edition
Press Releases on ALPMF
Changing Tomorrow Day 2014 Marks Astellas' Fifth Annual Global Service Initiative 1:22 a.m. Nov. 4, 2014 - PR Newswire - PRF
In 2023, Medivation/Astellas Pharma's Xtandi Will Be the Top-Selling Agent in the Prostate Cancer Market Across the United States, Europe, and Japan 12:00 p.m. Oct. 30, 2014 - PR Newswire - PRF
Vical Reports Third Quarter 2014 Financial Results and Progress in Key Development Programs 5:31 a.m. Oct. 30, 2014 - GlobeNewswire
QIAGEN Announces Broad Agreement With Astellas Pharma to Develop Companion Diagnostics 3:00 p.m. Oct. 28, 2014 - PR Newswire - PRF
Basilea reports protocol amendment resulting in earlier completion of isavuconazole phase 3 invasive candidiasis study 12:20 a.m. Oct. 16, 2014 - GlobeNewswire
Basilea reports protocol amendment resulting in earlier completion of isavuconazole phase 3 invasive candidiasis study 12:16 a.m. Oct. 16, 2014 - Thomson Reuters ONE
Astellas Teams Up with USA Rugby and Men's Health Network to Encourage Chicagoans to Answer the Challenge for Better Health 9:00 a.m. Oct. 14, 2014 - PR Newswire - PRF
Astellas Announces Research Collaboration With Harvard Medical School Investigator For Treatment Of Retinal Degeneration 7:00 a.m. Oct. 14, 2014 - PR Newswire - PRF
Cytokinetics Announces Development Program Update for CK-2127107 6:31 a.m. Oct. 13, 2014 - Thomson Reuters ONE
Brian McLellan Promoted to President of Astellas Pharma Technologies 4:31 p.m. Oct. 1, 2014 - PR Newswire - PRF
U.S. FDA Approves New Indication for the Use of XTANDI® (enzalutamide) Capsules for Patients with Metastatic Castration-Resistant Prostate Cancer 3:39 p.m. Sept. 10, 2014 - PR Newswire - PRF
Cancer Research UK and Cancer Research Technology Join Forces with Astellas on Autophagy to Find New Cancer Treatments 8:00 a.m. Aug. 8, 2014 - PR Newswire - PRF
Vical Reports Second Quarter 2014 Financial Results and Progress in Key Development Programs 5:02 a.m. July 31, 2014 - GlobeNewswire
Global Parkinson%s Disease Market 2014-2018 5:42 p.m. July 28, 2014 - PR Newswire - PRF
Global Pharmaceutical Survey 2013-2014 - Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry 3:27 p.m. July 15, 2014 - PR Newswire - PRF
Donna Ambrosino Joins ClearPath Vaccines Company as Chief Medical Officer 8:00 a.m. July 15, 2014 - PR Newswire - PRF
Veloxis Announces Positive Two-Year Results from Pivotal Phase 3 Study of Envarsus® XR (tacrolimus extended-release tablets) in de novo Kidney Transplant Patients 10:50 a.m. June 23, 2014 - PR Newswire - PRF
Astellas Pharma Returns to 'Give Kids The World' and Expands Partnership with Starlight Children's Foundation to Brighten the Lives of Young Patients & Their Families 8:00 a.m. June 11, 2014 - PR Newswire - PRF
Nidec Corp. Retains Top Spot on Institutional Investor's All-Japan Executive Team 1:45 a.m. June 5, 2014 - Marketwire
New England Journal of Medicine Publishes Results From Phase 3 PREVAIL Trial of Enzalutamide in Men With Chemotherapy-Naive Metastatic Prostate Cancer Progressing Despite Androgen Deprivation Therapy 8:02 a.m. June 1, 2014 - Marketwire
Loading more headlines...

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bank of America Faces Class-Action Suit in Court

Mixed Bag for Bank of America Investors If you thought you could just park your cash in big banks and slumber through the financial year, think again. Bank of America (NYSE: BAC) has found itself in hot water with a securities fraud class-action suit looming over what some are calling a pretty nasty oversight in compliance. A 4.76% stock drop was a bitter sip for those...

2026 Diamond Certified Directory: A Trustworthy Guide

A Refreshing Reality in a Sea of Online Reviews Imagine having a compass that actually points you in the right direction through the foggy mess of online reviews. That's what the Fall 2026 Diamond Certified Directory aims to be. This ain't some random collection of opinions. This is hard-hitting, reliable information that's been battle-tested in the real world. We're...

BETR Faces Shareholder Suit After Plummeting Stock

Better Home & Finance Navigates Turbulent Waters Not every day the news comes up smelling of roses, and that's putting it lightly for Better Home & Finance, trading as NASDAQ: BETR. When you're talking about a splash that sends shockwaves, losing over 28% of your stock value on a single trading day is one whale of a splash indeed. The Numbers That Shook the Waters It's no...

Latham & Watkins Welcomes Privacy Sledgehammer Macko

Privacy Enforcer Lands at Latham & Watkins With regulatory pressure turning up the heat, Latham & Watkins has roped in Michael Macko, a seasoned pro when it comes to privacy enforcement. To give you a peek into his credibility, Macko doesn't just have a foot in the door—he built the doorframe himself over at the California Privacy Protection Agency (CalPrivacy)....

SLM Hit by Earnings Miss: Shareholders Eye Legal Action

When A Profit Turns To Loss There's a certain sting that comes with expecting a profit only to get smacked with a loss. You know the kind—like when SLM Corporation shareholders had their expectations shattered on October 22, 2026. They figured they'd see a $0.17 profit per share, but what landed instead was a $0.19 loss. That's a $0.36-per-share swing, enough to make...

Fair Play in Focus: SYNA, CSR, VCTR, EFSI Deals Scrutinized

The Corporate Buzz: Deals Under the Microscope Riding the rollercoaster of mergers and acquisitions ain't new in the stock market realm. But when the stakes seem one-sided, alarms start ringing. Halper Sadeh LLC, a firm that cuts its teeth on this kind of corporate sleuthing, is all hands on deck probing a slew of big deals involving Synaptics (NASDAQ:SYNA), Centerspace...

CPSC's Management Overhaul: Progress or Just Polishing?

The Tangled Web of Bureaucracy Ah, the Consumer Product Safety Commission—CPSC for short. It's like the Secretariat of product safety, but often knee-deep in old problems. Over the years, hearing about their challenges is like flipping through a well-worn playbook. But now, the talk is all about a fresh page under Acting Chairman Peter A. Feldman. The watchdog in...

111, Inc. Strategizes with Advisors Amid Proposal Talks

Every time a company's board starts tossing around phrases like "strategic alternatives," you’ve got to pay closer attention. 111, Inc., holding the NASDAQ ticker YI, is one such entity at a crossroads. They've enlisted Houlihan Lokey China Limited as their independent financial advisor and Kirkland & Ellis as their U.S. legal counsel to sift through potential strategic...

NOTHING NINE's Global Ambitions: Paris Show's Impact

Paris: Stage or Launchpad? You’d think walking that catwalk in Paris is the holy grail—fashion's own illustrious red carpet. But when you're Chloe, founder of NOTHING NINE, the real hustle kicks off once the lights dim. On 29th September 2026, this designer brand strutted its stuff at one of the grandest venues, Les Invalides, part of the prestigious Paris Fashion...

Better Home & Finance Faces 28.5% Stock Plunge, Lawsuit

The Sudden Dive in Better Home's Stock Imagine cruising down the highway with the wind in your hair and suddenly slamming into a pothole. That's the kind of jarring experience Better Home & Finance Holding Company (NASDAQ: BETR) investors felt when the stock took a nosedive, diving a hefty 28.5%. Back on May 7, 2026, the company released financial figures that flipped the...